In great contrast, the aberrant MYC pathway more frequently co-occurred with KIF5B-RET than CCDC6-RET (7.8% vs. 0.0%, P < 0.001) in baseline RET-rearranged patients with NSCLC. This evidence concerns the gene KIF5B and non-small cell lung carcinoma.